Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants

Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized... Key PointsQuestionIs the use of a placebo run-in (PRI) period associated with different outcomes among randomized clinical trials (RCTs) of antidepressants? FindingsIn this systematic review and meta-analysis of 347 RCTs of antidepressants comprising 89 183 participants, the use of PRI periods was associated with a lower placebo and drug response but was not associated with the drug-placebo difference. MeaningThis study suggests that the use of PRI periods is common in RCTs of antidepressants, despite offering no apparent benefits to RCT outcomes; given the risks and costs of PRI periods, their practice should be ceased. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants

Loading next page...
 
/lp/american-medical-association/association-of-single-blind-placebo-run-in-periods-with-the-placebo-aS4RekGinC
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2021.3204
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs the use of a placebo run-in (PRI) period associated with different outcomes among randomized clinical trials (RCTs) of antidepressants? FindingsIn this systematic review and meta-analysis of 347 RCTs of antidepressants comprising 89 183 participants, the use of PRI periods was associated with a lower placebo and drug response but was not associated with the drug-placebo difference. MeaningThis study suggests that the use of PRI periods is common in RCTs of antidepressants, despite offering no apparent benefits to RCT outcomes; given the risks and costs of PRI periods, their practice should be ceased.

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jan 10, 2022

References